What Are the Differences in Treatment Options Between Glioma and Glioblastoma?

Glioma and glioblastoma (GBM) are among the most common primary brain tumor types. After diagnosis, many patients notice that these two terms often appear together, which can easily lead to the misunderstanding that they refer to the same disease.

In fact, glioblastoma is a type of glioma, but it represents the most aggressive form and is classified as a WHO Grade IV central nervous system tumor.

Compared with low-grade gliomas, glioblastoma grows faster, is more invasive, has a higher risk of recurrence, and therefore requires a more complex treatment strategy.

In this article,HongKong DengYueMed will provide a comprehensive overview of current treatment options for both conditions, including surgery, radiotherapy, drug therapy, and emerging therapies, and highlight their key differences.

Why Is Glioblastoma Treatment Usually More Complex?

The differences in treatment strategies primarily come from the biological behavior of the disease itself.

Low-grade gliomas generally grow slowly, and some patients can achieve long-term disease stability after standard treatment.

In contrast, glioblastoma has the following characteristics:

● Fast tumor growth

● Strong invasiveness

● High tendency to infiltrate surrounding brain tissue

● High recurrence rate

● Poorer prognosis

Therefore, glioblastoma often requires more aggressive and comprehensive treatment strategies, while some glioma patients may be managed with relatively conservative approaches.

Surgical Treatment: Different Treatment Goals

Glioma

For most glioma patients, surgery is the first step in treatment.

Treatment goals include:

● Confirming pathological diagnosis

● Obtaining tissue for molecular testing

● Maximizing tumor resection

● Preserving neurological function

● Delaying disease progression

For some low-grade glioma patients, if the tumor is located in an operable area and is fully resected, postoperative follow-up alone may be sufficient.

Glioblastoma

Glioblastoma patients also require surgical treatment.

However, due to unclear tumor borders and strong infiltrative behavior, complete resection is usually not possible.

Therefore, the main goals of surgery are:

● Maximal safe tumor resection

● Relief of neurological compression symptoms

● Reduction of tumor burden

● Preparation for further treatment

Radiotherapy: Standard of Care for Glioblastoma

Glioma

Not all glioma patients require immediate radiotherapy.

Patients who may be monitored without immediate radiation include:

● Younger age

● Complete tumor resection

● Low-risk molecular features

For high-grade gliomas, postoperative radiotherapy is usually required.

Glioblastoma

For glioblastoma patients, postoperative radiotherapy is considered a standard treatment.

Common approaches include:

● Intensity-modulated radiotherapy (IMRT)

● Volumetric modulated arc therapy (VMAT)

● Proton therapy

Radiotherapy is typically started within weeks after surgery to control residual tumor cells.

Chemotherapy: Significant Differences in Use

Glioma

The need for chemotherapy depends on:

● Tumor grade

● IDH mutation status

● 1p/19q co-deletion status

● Patient age

● Extent of surgical resection

Common drugs include temozolomide, one of the most widely used chemotherapeutic agents for brain gliomas.

The PCV regimen includes:

● Lomustine

● Procarbazine

● Vincristine

This regimen is particularly important in certain oligodendroglioma patients.

Glioblastoma

Temozolomide is the core chemotherapy drug for glioblastoma treatment.

The internationally recommended standard protocol is the Stupp regimen:

Phase 1:

● Radiotherapy

● Concurrent temozolomide

Phase 2:

● Adjuvant temozolomide

This regimen is currently the global standard of care for glioblastoma.

Targeted Therapy: Focused on Specific Molecular Subtypes

With the development of precision medicine, some glioma patients benefit from targeted therapy.

Glioma

One of the most important recent advances is IDH inhibition therapy.

Representative drug: Vorasidenib

It is mainly used for:

● IDH1-mutant glioma

● IDH2-mutant glioma

Studies show that it can delay disease progression and postpone the need for further treatment in some patients.

Glioblastoma

At present, glioblastoma does not have widely approved targeted therapies comparable to those used in other cancers such as EGFR inhibitors in lung cancer.

Most agents remain under clinical investigation.

Bevacizumab: Mainly Used in Recurrent Glioblastoma

Glioma

Bevacizumab has limited use in routine glioma treatment.

Glioblastoma

Bevacizumab is an anti-VEGF monoclonal antibody.

Its main effects include:

● Inhibition of tumor angiogenesis

● Reduction of brain edema

● Improvement of neurological symptomsIt is commonly used in:

● Recurrent glioblastoma

● Refractory brain edema

Tumor Treating Fields (TTFields): More Relevant for GBM

Glioma

Currently, its use is limited.

Glioblastoma

Tumor Treating Fields (TTFields) is an emerging treatment technology.

Representative device:

● Optune®

It uses low-intensity alternating electric fields to disrupt tumor cell division and inhibit tumor growth.

It has been included in multiple international treatment guidelines.

Immunotherapy and Cell Therapy: Focus on Glioblastoma Research

Glioma

Research in this area is still limited, and no standardized immunotherapy has been established.

Glioblastoma

Due to the limited effectiveness of conventional therapies, glioblastoma has become one of the most active areas of immunotherapy research.

Key approaches include:

PD-1 inhibitors

Examples:

● Nivolumab

● Pembrolizumab

Tumor vaccines

Including:

● Dendritic cell (DC) vaccines

● Personalized neoantigen vaccines

CAR-T therapy

Main targets under investigation include:

● EGFRvIII

● HER2

● IL13Rα2

● B7-H3Although most therapies are still in clinical trials, they are considered important future directions.

Summary of Treatment Differences Between Glioma and Glioblastoma

Although glioblastoma is a subtype of glioma, their treatment strategies differ significantly.

Overall, low-grade gliomas focus more on long-term disease control and quality of life, while glioblastoma requires a more aggressive and multidisciplinary treatment strategy. With the development of Vorasidenib, TTFields, CAR-T cell therapy, and other innovative approaches, brain tumor treatment is entering a more precise and personalized era.

Global pharmaceutical distributor DengYueMed will continue to monitor developments in glioma and glioblastoma research, including new drug development, clinical trial progress, and global treatment trends, providing the latest insights into medical innovation worldwide.